JAMA Psychiatry最新文献

{"title":"Association of State Cannabis Legalization With Cannabis Use Disorder and Cannabis Poisoning.","authors":"Jayani Jayawardhana, Jialin Hou, Patricia Freeman, Jeffery C Talbert","doi":"10.1001/jamapsychiatry.2024.4145","DOIUrl":"10.1001/jamapsychiatry.2024.4145","url":null,"abstract":"<p><strong>Importance: </strong>Whether state implementation of medical and recreational cannabis laws is associated with increased cannabis use disorder (CUD) and/or cannabis poisoning among adults is not evident.</p><p><strong>Objective: </strong>To examine state-level medical and recreational cannabis laws' associations with CUD and cannabis poisoning, overall and by sex and age subgroups.</p><p><strong>Design, setting, and participants: </strong>In this longitudinal cohort study, state-level CUD and cannabis poisoning diagnoses from January 2011 to December 2021 were examined across all 50 US states and the District of Columbia before and after the implementation of medical and recreational cannabis laws (MCLs and RCLs, respectively) using a staggered adoption difference-in-differences approach. Event studies were conducted to estimate the magnitude of the association for each year-quarter relative to the time of each policy implementation. This study was conducted among all adults aged 18 to 64 years enrolled in the Merative MarketScan Commercial Claims and Encounters Database, a database of employer-sponsored health insurance enrollees, with 1 year or more of continuous enrollment from 2011 to 2021. Data analysis was performed from January to August 2024.</p><p><strong>Exposures: </strong>State implementation of an MCL, opening a medical cannabis dispensary (MCD), allowing home cultivation of medical cannabis (HC-MC), and passage of an RCL.</p><p><strong>Main outcomes and measures: </strong>CUD and cannabis poisoning diagnoses per 100 000 enrollees per quarter.</p><p><strong>Results: </strong>This study included 110 256 536 enrollees, of whom 56 843 030 (52%) were female and the mean (SD) enrollee age was 41.0 (13.5) years. MCLs were associated with significant increases in CUD and cannabis poisoning by 31.09 (95% CI, 20.20-41.99; P < .001) and 0.76 (95% CI, 0.52-1.00; P < .001) diagnoses per 100 000 enrollees per quarter, respectively, and RCLs were associated with a significant increase in cannabis poisoning by 0.34 (95% CI, 0.19-0.48; P < .001) per 100 000 enrollees per quarter in states with RCLs compared to states without these laws. No significant associations were observed for MCDs or HC-MC. Relative increases in CUD associated with MCLs were higher among female enrollees and among enrollees aged 35 to 44 years compared with male enrollees and other age groups, respectively. Sensitivity analysis results of 2011 to 2019 data were consistent with the 2011 to 2021 results.</p><p><strong>Conclusions and relevance: </strong>In this longitudinal cohort study, MCLs were associated with increased CUD and cannabis poisoning diagnoses, and RCLs were associated with increased cannabis poisoning in adults aged 18 to 64 years with employer-sponsored health insurance. Communities with increased access to cannabis may experience increased health care use and costs due to increases in cannabis poisoning and CUD, and new clinical and policy intervent","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"228-236"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medically Recommended vs Nonmedical Cannabis Use Among US Adults.","authors":"Beth Han, Wilson M Compton, Emily B Einstein, Nora D Volkow","doi":"10.1001/jamapsychiatry.2024.4475","DOIUrl":"10.1001/jamapsychiatry.2024.4475","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"319-321"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Left Ventrolateral Prefrontal Cortical Activity During Reward Expectancy and Mania Risk.","authors":"Manan Arora, Henry Chase, Michele A Bertocci, Alexander S Skeba, Kristen Eckstrand, Genna Bebko, Haris A Aslam, Robert Raeder, Simona Graur, Osasumwen Benjamin, Yiming Wang, Richelle S Stiffler, Mary L Phillips","doi":"10.1001/jamapsychiatry.2024.4216","DOIUrl":"10.1001/jamapsychiatry.2024.4216","url":null,"abstract":"<p><strong>Importance: </strong>Mania/hypomania is the pathognomonic feature of bipolar disorder (BD). As BD is often misdiagnosed as major depressive disorder (MDD), replicable neural markers of mania/hypomania risk are needed for earlier BD diagnosis and pathophysiological treatment development.</p><p><strong>Objective: </strong>To replicate the previously reported positive association between left ventrolateral prefrontal cortex (vlPFC) activity during reward expectancy (RE) and mania/hypomania risk, to explore the effect of MDD history on this association, and to compare RE-related left vlPFC activity in individuals with and at risk of BD.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study was conducted from July 2014 to December 2023 at the University of Pittsburgh, Pittsburgh, Pennsylvania. Three samples were formed comprising young adults (aged 18 to 30 years) without BD and with a range of subsyndromal-syndromal affective and anxiety psychopathologies, including a new sample and 2 test samples from our previous research; a sample of individuals aged 18 to 30 years with euthymic BD was also included. All participants were recruited from the community through advertising.</p><p><strong>Exposures: </strong>Functional magnetic resonance imaging during an RE task.</p><p><strong>Main outcomes and measures: </strong>New sample: whole-brain activity during RE regressed to the Mood Spectrum Self-Report Lifetime Questionnaire (MOODS-SR-L) manic domain score in all participants and in those without history of MDD and RE-related whole-brain activity regressed to the MOODS-SR-L depressive domain score to determine specificity to mania/hypomania risk. Test samples: these associations were examined using parameter estimates of activity extracted from respective masks created from activity in the new sample. A tertile split of MOODS-SR-L manic domain score divided the new sample into 3 mania/hypomania risk groups. Comparison of RE-related activity (extracted parameter estimates) was performed in risk groups and individuals with BD.</p><p><strong>Results: </strong>Among the 113 individuals in the new sample, 73 were female, and the mean (SD) age was 23.88 (3.32) years. In each of the test samples, there were 52 individuals (39 female; mean [SD] age, 21.94 [2.12] years) and 65 individuals (47 female; mean [SD] age, 21.39 [2.11] years). The euthymic BD group had 37 individuals (30 female; mean [SD] age, 25.12 [3.81] years). In the new sample, 8 clusters of RE-related activity, including left vlPFC activity, showed a positive association with mania/hypomania risk, which remained after excluding individuals with MDD history and was specific to mania/hypomania risk. In the test samples, this association was shown in test sample 1 only (β, 0.21; 95% CI, 0.08-0.35; P = .002; q(false discovery rate [FDR]), 0.006; R2, 0.04). Test sample 2 had a higher proportion with MDD history (49 of 65 [75.3%] compared to 31 of 52 [59.6%] in sa","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"274-284"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Announcing \"Technology and Psychiatry\" and Expanding Evidence-Based Comments and Reviews in JAMA Psychiatry.","authors":"Dost Öngür, Roy H Perlis","doi":"10.1001/jamapsychiatry.2024.4573","DOIUrl":"10.1001/jamapsychiatry.2024.4573","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"215"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bright Light Therapy for Nonseasonal Depressive Disorders.","authors":"Hirofumi Hirakawa","doi":"10.1001/jamapsychiatry.2024.4480","DOIUrl":"10.1001/jamapsychiatry.2024.4480","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"324"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Requests for Medical Assistance in Dying by Young Dutch People With Psychiatric Disorders.","authors":"Lizanne J S Schweren, Sanne P A Rasing, Monique Kammeraat, Leah A Middelkoop, Ruthie Werner, Saskia Y M Mérelle, Julian M Garcia, Daan H M Creemers, Sisco M P van Veen","doi":"10.1001/jamapsychiatry.2024.4006","DOIUrl":"10.1001/jamapsychiatry.2024.4006","url":null,"abstract":"<p><strong>Importance: </strong>In the Netherlands, a growing group of young people request medical assistance in dying based on psychiatric suffering (MAID-PS). Little is known about this group, their characteristics, and outcomes.</p><p><strong>Objective: </strong>To assess the proportion of requests for and deaths by MAID-PS among young patients, outcomes of their application and assessment procedures, and characteristics of those patients who died by either MAID or suicide.</p><p><strong>Design, setting, and participants: </strong>This retrospective cohort study included Dutch individuals younger than 24 years requesting MAID-PS between January 1, 2012, and June 30, 2021, whose patient file had been closed by December 1, 2022, at the Expertisecentrum Euthanasie, a specialized health care facility providing MAID consultation and care.</p><p><strong>Main outcomes and measures: </strong>Outcomes of the MAID-PS assessment procedure (discontinued, rejected, or MAID-PS) and clinical characteristics of patients who died by MAID or suicide.</p><p><strong>Results: </strong>The study included 397 processed applications submitted by 353 individuals (73.4% female; mean [SD] age, 20.84 [1.90] years). Between 2012 and the first half of 2021, the number of MAID-PS applications by young patients increased from 10 to 39. The most likely outcome was application retracted by the patient (188 [47.3%]) followed by application rejected (178 [44.8%]). For 12 applications (3.0%), patients died by MAID. Seventeen applications (4.3%) were stopped because the patient died by suicide during the application process and 2 (0.5%) because the patient died after they voluntarily stopped eating and drinking. All patients who died by suicide or MAID (n = 29) had multiple psychiatric diagnoses (most frequently major depression, autism spectrum disorder, personality disorders, eating disorder, and/or trauma-related disorder) and extensive treatment histories. Twenty-eight of these patients (96.5%) had a history of suicidality that included multiple suicide attempts prior to the MAID application. Among 17 patients who died by suicide, 13 of 14 (92.9%) had a history of crisis-related hospital admission, and 9 of 12 patients who died by MAID (75.0%) had a history of self-harm.</p><p><strong>Conclusions and relevance: </strong>This cohort study found that the number of young psychiatric patients in the Netherlands who requested MAID-PS increased between 2012 and 2021 and that applications were retracted or rejected for most. Those who died by MAID or suicide were mostly female and had long treatment histories and prominent suicidality. These findings suggest that there is an urgent need for more knowledge about persistent death wishes and effective suicide prevention strategies for this high-risk group.</p>","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"246-252"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Vaccination Really Mitigate Psychiatric Implications of COVID-19?-Reply.","authors":"Venexia M Walker, Praveetha Patalay, Jonathan A C Sterne","doi":"10.1001/jamapsychiatry.2024.4099","DOIUrl":"10.1001/jamapsychiatry.2024.4099","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"323-324"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What the Experiences of Young Persons Can Teach Us About Medical Aid in Dying for Psychiatric Illness.","authors":"Brent Kious","doi":"10.1001/jamapsychiatry.2024.3963","DOIUrl":"10.1001/jamapsychiatry.2024.3963","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"216-217"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Employment Nondiscrimination Protection and Mental Health Among Sexual Minority Adults.","authors":"Michael Liu, Vishal R Patel, Sahil Sandhu, Rishi K Wadhera, Alex S Keuroghlian","doi":"10.1001/jamapsychiatry.2024.4318","DOIUrl":"10.1001/jamapsychiatry.2024.4318","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;In the 2020 Bostock v Clayton County decision, the US Supreme Court extended employment nondiscrimination protection to sexual minority adults. The health impacts of this ruling and similar policies related to sexual orientation-based discrimination are not currently known.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To estimate changes in mental health following the Bostock decision among sexual minority adults in states that gained employment nondiscrimination protection (intervention states) compared with those in states with protections already in place (control states).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This cross-sectional study used 2018-2022 data from the Behavioral Risk Factor Surveillance System and a difference-in-differences approach to evaluate changes in mental health after the Bostock decision by comparing sexual minority adults (aged ≥18 years and identifying as lesbian, gay, or bisexual) in 12 intervention states with those residing in 9 control states. Models were estimated for all participants and separately for employed participants. Data were analyzed between February and September 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposure: &lt;/strong&gt;Residing in a state that gained employment nondiscrimination protection after the Bostock decision.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The primary outcome was number of poor mental health days during the past 30 days, and the secondary outcome was severe mental distress (defined as 14 or more past-month poor mental health days).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of 597 462 participants (306 365 in intervention states [77.7% aged 18-64 years and 22.3% aged ≥65 years; 51.7% female] and 291 097 in control states [77.5% aged 18-64 years and 22.5% aged ≥65 years; 50.6% female]), 5.1% in intervention states and 6.0% in control states self-identified as sexual minority adults. The mean (SE) number of past-month poor mental health days was unchanged after the Bostock decision among sexual minority adults in both intervention (from 8.70 [0.27] to 9.59 [0.24] days; adjusted difference, 0.57 [95% CI, -1.02 to 2.16] days) and control (from 8.53 [0.21] to 10.15 [0.20] days; adjusted difference, 1.17 [95% CI, -0.46 to 2.79] days) states, resulting in no differential change between the 2 groups (difference-in-differences, -0.60 days; 95% CI, -1.25 to 0.06 days). Among the subset of employed sexual minority adults, the mean (SE) number of poor mental health days did not change in intervention states (from 7.99 [0.38] to 8.83 [0.30] days; adjusted difference, 0.87 [95% CI, -0.49 to 2.22] days) but increased in control states (from 7.75 [0.27] to 9.75 [0.26] days; adjusted difference, 1.84 [95% CI, 0.44-3.24] days). These findings corresponded to a significant relative reduction in poor mental health days among employed sexual minority adults in intervention vs control states (difference-in-differences, -0.97 days; 95% CI, -1.74 to -0.21 days). Mean (SE) rates of sever","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"237-245"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depressive Symptoms and Amyloid Pathology.","authors":"Wietse A Wiels, Julie E Oomens, Sebastiaan Engelborghs, Chris Baeken, Christine A F von Arnim, Mercè Boada, Mira Didic, Bruno Dubois, Tormod Fladby, Wiesje M van der Flier, Giovanni B Frisoni, Lutz Fröhlich, Kiran Dip Gill, Timo Grimmer, Helmut Hildebrandt, Jakub Hort, Yoshiaki Itoh, Takeshi Iwatsubo, Aleksandra Klimkowicz-Mrowiec, Dong Young Lee, Alberto Lleó, Pablo Martinez-Lage, Alexandre de Mendonça, Philipp T Meyer, Elisabeth N Kapaki, Piero Parchi, Matteo Pardini, Lucilla Parnetti, Julius Popp, Lorena Rami, Eric M Reiman, Juha O Rinne, Karen M Rodrigue, Pascual Sánchez-Juan, Isabel Santana, Marie Sarazin, Nikolaos Scarmeas, Ingmar Skoog, Peter J Snyder, Reisa A Sperling, Sylvia Villeneuve, Anders Wallin, Jens Wiltfang, Henrik Zetterberg, Rik Ossenkoppele, Frans R J Verhey, Stephanie J B Vos, Pieter Jelle Visser, Willemijn J Jansen, Daniel Alcolea, Daniele Altomare, Simone Baiardi, Ines Baldeiras, Randall J Bateman, Kaj Blennow, Michel Bottlaender, Anouk den Braber, Mark A van Buchem, Min Soo Byun, Jirí Cerman, Kewei Chen, Elena Chipi, Gregory S Day, Alexander Drzezga, Marie Eckerström, Laura L Ekblad, Stéphane Epelbaum, Stefan Förster, Juan Fortea, Yvonne Freund-Levi, Lars Frings, Eric Guedj, Lucrezia Hausner, Sabine Hellwig, Edward D Huey, Julio F Jiménez-Bonilla, Keith A Johnson, Ane Iriondo Juaristi, Ramesh Kandimalla, George Paraskevas, Silke Kern, Bjørn-Eivind S Kirsebom, Johannes Kornhuber, Julien Lagarde, Susan M Landau, Nienke Legdeur, Jorge J Llibre Guerra, Nancy N Maserejian, Marta Marquié, Shinobu Minatani, Silvia Daniela Morbelli, Barbara Mroczko, Eva Ntanasi, Catarina Resende de Oliveira, Pauline Olivieri, Adelina Orellana, Richard J Perrin, Oliver Peters, Sudesh Prabhakar, Inez H Ramakers, Eloy Rodríguez-Rodriguez, Agustín Ruiz, Eckart Rüther, Per Selnes, Dina Silva, Hilkka Soininen, Luiza Spiru, Akitoshi Takeda, Marc Teichmann, Betty M Tijms, Charlotte E Teunissen, Loisa I Thompson, Jonathan Vogelgsangs, Jonathan Vöglein, Gunhild Waldemar, Åsa K Wallin, Mary Yannakoulia, Dahyun Yi, Anna Zettergren","doi":"10.1001/jamapsychiatry.2024.4305","DOIUrl":"10.1001/jamapsychiatry.2024.4305","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Depressive symptoms are associated with cognitive decline in older individuals. Uncertainty about underlying mechanisms hampers diagnostic and therapeutic efforts. This large-scale study aimed to elucidate the association between depressive symptoms and amyloid pathology.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To examine the association between depressive symptoms and amyloid pathology and its dependency on age, sex, education, and APOE genotype in older individuals without dementia.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;Cross-sectional analyses were performed using data from the Amyloid Biomarker Study data pooling initiative. Data from 49 research, population-based, and memory clinic studies were pooled and harmonized. The Amyloid Biomarker Study has been collecting data since 2012 and data collection is ongoing. At the time of analysis, 95 centers were included in the Amyloid Biomarker Study. The study included 9746 individuals with normal cognition (NC) and 3023 participants with mild cognitive impairment (MCI) aged between 34 and 100 years for whom data on amyloid biomarkers, presence of depressive symptoms, and age were available. Data were analyzed from December 2022 to February 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Amyloid-β1-42 levels in cerebrospinal fluid or amyloid positron emission tomography scans were used to determine presence or absence of amyloid pathology. Presence of depressive symptoms was determined on the basis of validated depression rating scale scores, evidence of a current clinical diagnosis of depression, or self-reported depressive symptoms.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In individuals with NC (mean [SD] age, 68.6 [8.9] years; 5664 [58.2%] female; 3002 [34.0%] APOE ε4 carriers; 937 [9.6%] had depressive symptoms; 2648 [27.2%] had amyloid pathology), the presence of depressive symptoms was not associated with amyloid pathology (odds ratio [OR], 1.13; 95% CI, 0.90-1.40; P = .29). In individuals with MCI (mean [SD] age, 70.2 [8.7] years; 1481 [49.0%] female; 1046 [44.8%] APOE ε4 carriers; 824 [27.3%] had depressive symptoms; 1668 [55.8%] had amyloid pathology), the presence of depressive symptoms was associated with a lower likelihood of amyloid pathology (OR, 0.73; 95% CI 0.61-0.89; P = .001). When considering subgroup effects, in individuals with NC, the presence of depressive symptoms was associated with a higher frequency of amyloid pathology in APOE ε4 noncarriers (mean difference, 5.0%; 95% CI 1.0-9.0; P = .02) but not in APOE ε4 carriers. This was not the case in individuals with MCI.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;Depressive symptoms were not consistently associated with a higher frequency of amyloid pathology in participants with NC and were associated with a lower likelihood of amyloid pathology in participants with MCI. These findings were not influenced by age, sex, or education level. Mechanisms other than amyloid accumula","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"296-310"},"PeriodicalIF":22.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}